Group Financial Highlights
· Revenue £78.7m (2016: £80.7m)
· Gross profit up 12.9% to £49.1m (2016: £43.5m)
· Like-for-like1 gross profit growth of 5.4% (Constant currency: 2.4%)
· Headline profit before tax2 up 8.0% £4.6m (2016: £4.3m)
· Headline operating margin3 10.0% (2016: 10.3%)
· Headline basic earnings per share 3.43p (2016: 3.60p)
· Statutory profit before tax of £2.7m (2016: loss of £0.8m)
· Statutory basic earnings per share 2.16p (2016: loss of 1.08p)
· Net debt £6.8m (June 2016: £4.8m)
· Interim dividend up 5.0% to 1.05p (2016: 1.00p)
· Equity placing raised £14.2m (net) in February 2017
Divisional Financial Highlights
|
H1 |
Cello Health |
Cello Signal |
||||
|
£'000 |
2017 |
2016 |
% Growth |
2017 |
2016 |
% Growth |
|
Segmental gross profit |
28,087 |
22,162 |
26.7% |
19,851 |
20,714 |
(4.2)% |
|
Headline operating profit |
4,876 |
3,906 |
24.8% |
1,197 |
1,694 |
(29.3)% |
|
Headline operating margin |
17.4% |
17.6% |
|
6.0% |
8.2% |
|
Operating Highlights
· Continued rapid growth of Cello Health both organically and by acquisition
· Successful acquisition of Defined Health in February 2017
· Continued fast growth of Pulsar helped by US launch
· Post period end acquisition of Advantage Health
· Cello Signal on track to achieve expectations
Mark Scott, Chief Executive, commented: “It has been an encouraging first half for the Group. Cello Health's strategy of focusing on expansion in the US is progressing well. The acquisition of Defined Health in February this year has already made a good contribution and we are very pleased with its integration in Cello Health which is also achieving strong organic growth, particularly in the US. Cello Signal is on track to meet expectations. The Board is therefore confident of meeting market expectations for the year and is pleased to increase the interim dividend.”